Sona completes treatment of first patient cohort in FS

Mr. David Regan reports SONA PROVIDES UPDATE ON FIRST-IN-HUMAN CLINICAL TRIAL Sona Nanotech Inc. has provided an update on the first-in-human early feasibility study of its Targeted Hyperthermia therapy (THT) cancer treatment with late-stage melanoma patients. The treatment and follow-up assessments of the first cohort of patients have now been completed, and treatment on the second cohort of patients has been approved with Sona's chief medical officer, arriving in Santiago this past weekend to oversee further treatments. Sona CMO, Dr. Carman Giacomantonio, commented: "We are very pleased with the progress of our early feasibility study, which has provided rich learnings in the real-world application our THT therapy in humans. It has been a pleasure to work with the clinicians and research team at Bradford Hill. We have treated a variety of melanoma tumour types in our first cohort and have encountered no significant adverse health events in patients. As we proceed with the second cohort of patients, we have reason for optimism based on early clinical responses and tumour biopsy results for patients treated so far. We look forward to completing the targeted number of patients by the end of September and then running the more extensive scientific analysis to fully assess immune engagement in treated tumours following THT." David Regan, Sona's chief executive officer, commented: "We are encouraged by the progress of our first-in-human clinical study and pleased to be progressing toward having validating clinical data that will further complement our existing preclinical data. We also excitedly anticipate additional scientific insights into our novel technology from studies planned for submission to leading scientific journals in the fall that, combined with our clinical study, will provide for a more comprehensive data package. Furthermore, with our previously announced ethics approval secured for a larger clinical trial in Canada, we are currently working to incorporate the significant learnings to date from our early feasibility study into our application to Health Canada." About Sona Nanotech Inc. Sona Nanotech is developing Targeted Hyperthermia, a photothermal cancer therapy that uses therapeutic heat to treat solid cancer tumours. The heat is delivered to tumours by infrared light that is absorbed by Sona's gold nanorods in the tumour and re-emitted as heat. Therapeutic heat (42 C to 48 C) stimulates the immune system, shrinks tumours, inactivates cancer stem cells and increases tumour perfusion -- thus enabling drugs to reach all tumour compartments more effectively. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments. Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles that it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium (CTAB) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. We seek Safe Harbor.